These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 9491842

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia.
    Zimmermann AE, Katona BG, Plaisance KI.
    Pharmacotherapy; 1995; 15(1):85-91. PubMed ID: 7739950
    [Abstract] [Full Text] [Related]

  • 4. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
    Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM.
    Pharmacotherapy; 1990; 10(6):378-82. PubMed ID: 2287556
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis.
    Meng L, Fang Y, Chen Y, Zhu H, Long R.
    J Chemother; 2015 Aug; 27(4):213-20. PubMed ID: 24641266
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study.
    Bhatt-Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T.
    Pediatrics; 1999 Apr; 103(4):e48. PubMed ID: 10103340
    [Abstract] [Full Text] [Related]

  • 9. Incidence and predictors of vancomycin-associated nephrotoxicity.
    Moh'd H, Kheir F, Kong L, Du P, Farag H, Mohamad A, Zurlo JJ.
    South Med J; 2014 Jun; 107(6):383-8. PubMed ID: 24945176
    [Abstract] [Full Text] [Related]

  • 10. Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study.
    Barberan J, Mensa J, Artero A, Epelde F, Rodriguez JC, Ruiz-Morales J, Calleja JL, Guerra JM, Martínez-Gil I, Giménez MJ, Granizo JJ, Aguilar L.
    Rev Esp Quimioter; 2019 Feb; 32(1):22-30. PubMed ID: 30630306
    [Abstract] [Full Text] [Related]

  • 11. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
    Han HK, An H, Shin KH, Shin D, Lee SH, Kim JH, Cho SH, Kang HR, Jang IJ, Yu KS, Lim KS.
    Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.
    Cies JJ, Shankar V.
    Pharmacotherapy; 2013 Apr; 33(4):392-400. PubMed ID: 23471688
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.
    Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ.
    Pharmacotherapy; 2012 Mar; 32(3):195-201. PubMed ID: 22392452
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China.
    Dong MH, Wang JW, Wu Y, Chen BY, Yu M, Wen AD.
    Int J Infect Dis; 2015 Aug; 37():125-8. PubMed ID: 26159843
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.